TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
AFT Leaves X Over AI-Generated Images of Minors 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
IRVINE, Calif., April 03, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against NantHealth, Inc. (“NantHealth” or the “Company”) (Nasdaq:NH). Investors who purchased shares (1) pursuant and/or traceable to the Company’s initial public offering (“IPO”) on or about June 1, 2016; and/or (2) between June 1, 2016 and March 6, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the May 8, 2017 lead plaintiff motion deadline.
If you purchased shares of NantHealth during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that during the Class Period, NantHealth made materially false and/or misleading statements and/or failed to disclose: that its founder Patrick Soon-Shiong had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; that NantHealth and Soon-Shiong violated federal tax laws; that the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; and that the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016. When this information reached the public, shares of NantHealth dropped in value, thus harming investors.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
